China Sanjiang Fine Chemicals Company Limited (2198.HK) - Deep Dive

Basic Materials / Commodity & Fine Chemicals - Main Board, Hong Kong Stock Exchange

A note on reporting cadence and "concalls": China Sanjiang is a Cayman-incorporated, Hong Kong-listed manufacturer with a December 31 fiscal year-end. Like almost all HKEX-listed mainland industrials of its size, it reports half-yearly (interim results in August, full-year results in late March) and does not hold quarterly earnings conference calls or publish transcripts. There is therefore no library of six quarterly transcripts to draw on. In their place I use the company's six most recent half-yearly results announcements and the management discussion and analysis contained in each, which is the equivalent management communication for this issuer. The six periods are:

1. H1 2023 interim - announced ~Sept 1, 2023
2. FY2023 annual - announced ~March 28, 2024
3. H1 2024 interim - announced Aug 30, 2024
4. FY2024 annual - announced March 28, 2025
5. H1 2025 interim - announced ~late August 2025
6. FY2025 annual - announced ~March 28, 2026

Working the cadence forward from today (2026-07-31): the most recent released period is FY2025 (late March 2026). The next release, H1 2026 interim results, is due in the second half of August 2026 (the company has historically filed around Aug 26-30). It is not yet released; that is the normal half-yearly gap, not a delay. It may surface within a few weeks of this report. All analysis below is anchored to FY2025 as the latest verified period.

1. What the Company Does

China Sanjiang Fine Chemicals turns two cheap raw materials - purchased ethylene and its own refinery-style olefin streams - into ethylene oxide (EO) and a fan of derivatives that go into antifreeze, polyester, detergents, construction admixtures, and plastics. In plain terms, it is a merchant ethylene oxide and ethylene glycol producer sitting in the Yangtze River Delta, the densest chemical-consuming region in China, and it sells the molecules that thousands of downstream factories around it need but cannot economically make themselves.

The company was founded in December 2003 as Jiaxing Sanjiang Chemical Co., Ltd. by a married couple, Guan Jianzhong and Han Jianhong, in Jiaxing, Zhejiang Province. The founding rationale was specific and geographic: in the early 2000s East China had a structural shortage of ethylene oxide, a molecule that is dangerous to transport over long distances (it is flammable, toxic, and prone to runaway reaction), so it has to be made close to where it is consumed. Sanjiang built EO capacity right next to the region's surfactant, antifreeze, and polyester customers and became one of the few large privately owned merchant EO suppliers in a market otherwise dominated by the state oil majors. It listed on the Hong Kong Main Board in September 2010 under code 2198.

The technical heart of the business is that ethylene oxide is hard to make and hard to move. Producing it requires a silver-catalyst partial-oxidation reactor operating within a narrow, closely controlled window - too much oxygen and the reaction runs away, too little and yield collapses. Because merchant (loose, sellable) EO cannot be shipped far, a producer's value comes from location plus scale plus reliability: being physically embedded in a cluster of customers, running a very large single-train unit at high utilisation to drive unit costs down, and being trusted to deliver a hazardous product safely every day. Sanjiang's EO facility has a nameplate of roughly 1.6 million tonnes per year, with a supporting 1 million tonne EO/EG combined unit that management has described as the largest single-unit facility of its kind in China.

What makes the business interesting - and volatile - is the flexibility built into the site. The same feedstock streams can be swung between ethylene glycol (a bulk commodity tied to polyester), merchant EO (sold to surfactant and construction-chemical makers at a premium to EG), polypropylene, MTBE, butadiene and other C4/C5 by-products depending on which spread is widest that month. In good conditions that optionality is a margin lever; in a downcycle it is a hedge that keeps the plant full even when any single product is unprofitable.

The essence of the model was on display in FY2024, the first full year after a major facility upgrade: with the same asset base, ethylene glycol sales volume rose roughly 85% and butadiene volume more than doubled (up ~105%), driving net profit up nearly fivefold. The plant did not get bigger; management simply pointed more of its molecules at whichever product was paying.

2. Business Segments

China Sanjiang runs as a single integrated petrochemical site, not a group of distinct divisions with separate management and economics. It does not report clean stand-alone segment P&Ls the way a conglomerate would; instead it reports one manufacturing business with several product lines fed from a shared cracking/oxidation complex. Because those product lines have genuinely different end markets, customers, and competitive dynamics, I treat them as sub-segments below - but the reader should hold in mind that they share the same feedstock, the same site, and the same fixed-cost base, which is exactly why management can swing output between them.

2.1 Ethylene Oxide and Ethylene Glycol (the core)

This is the reason the company exists and the largest slice of revenue. Merchant EO is sold to nearby makers of nonionic surfactants and, increasingly, to producers of polycarboxylate (PCE) water-reducer monomers used in concrete. Ethylene glycol (MEG) is the bulk commodity leg, feeding polyester fibre and PET resin. The core capability here is operating a very large EO train safely at high utilisation and being able to shift the EO/EG split toward whichever is more profitable - merchant EO usually carries a premium over glycol, so when surfactant and construction demand is strong the company skews toward EO, and when it is weak it dumps the molecules into glycol to keep the reactor full. This is the margin engine when spreads are healthy and the shock absorber when they are not. It was also the main source of FY2025 pain: management specifically flagged margin compression in ethylene oxide and lower ethylene contribution as the reason profit slid, even as glycol volumes held up.

2.2 Surfactants and Water-Reducing Agent Monomers

Sanjiang converts part of its EO downstream into AEO-type nonionic surfactants (used in detergents, textile auxiliaries, agrochemical wetting agents) and into the polyether monomers that go into PCE superplasticisers for concrete. This is the higher-value, "fine chemical" end of the name. It exists as a distinct line because it serves a completely different customer base (consumer-goods and construction-chemical formulators, not polyester mills) and because the construction-admixture monomer market has been the fastest-growing outlet for EO in China. Management called surfactants a resilient contributor in FY2025 - a diversifier that held margin while the commodity legs compressed.

2.3 Polypropylene (PP)

A plastics leg fed from the site's propylene stream, sold as resin to converters, and also offered as a processing (tolling) service where a customer supplies feedstock and Sanjiang runs it through the plant for a fee. PP broadens the product slate and monetises the propylene by-product. The tolling/processing model is important because it generates fee income that is insulated from resin price swings - the company gets paid for capacity and know-how rather than taking commodity price risk.

2.4 Olefin and Aromatic By-products (MTBE, C4/Butadiene, Pentene)

The cracking and refining operations throw off MTBE (a gasoline blendstock), C4 streams including butadiene (synthetic rubber feedstock), crude pentene, and other olefins. These are opportunistic, price-driven sales. Butadiene was a standout in FY2024 (volume up ~105%, ASP up ~51%), then part of the "olefin and aromatics by-product" margin squeeze that hurt FY2025. Management uses this basket as a flexibility valve: when butadiene or MTBE spreads are wide, more C4 is pushed there; when they collapse, molecules go back into the glycol/EO core.

2.5 Industrial Gases and Other Services

The site also produces and supplies oxygen, nitrogen and argon (needed for its own oxidation chemistry, with surplus sold locally) and provides processing services for PP, MTBE and surfactants. This is a small, steady, utility-like tail that improves site economics.

3. Products and Business Detail

Full catalogue. The company's saleable product set spans: ethylene oxide (merchant, sold loose to derivative makers); ethylene glycol (mono-ethylene glycol for polyester and antifreeze, plus di-/tri-ethylene glycol grades); polypropylene resin; nonionic surfactants (AEO family) and polycarboxylate water-reducer polyether monomers; ethanolamine (an EO+ammonia derivative used in gas treating, agrochemicals, and detergents); MTBE; C4 streams and butadiene; crude pentene; and industrial gases (oxygen, nitrogen, argon). On top of product sales it runs tolling/processing services for PP, MTBE and surfactants.

Why the products are hard to make. The gating technology is the EO reactor: a silver-catalysed direct-oxidation process where ethylene and oxygen react on a supported silver catalyst under tight temperature, pressure and oxygen-concentration control. Run it wrong and you get runaway oxidation (a safety event) or catalyst deactivation (a yield and cost problem). Catalyst selectivity and reactor uptime are the difference between a profitable EO unit and a loss-making one, and both take years of operating experience to optimise. EO is also classified as a hazardous, highly flammable, toxic and carcinogenic material, so the plant carries a heavy process-safety, permitting and environmental-compliance burden that a new entrant cannot short-cut. That regulatory and safety moat is part of why merchant EO supply is concentrated.

Manufacturing footprint. Production is concentrated at the Jiaxing, Zhejiang complex in the Yangtze River Delta, deliberately sited among the region's polyester mills, surfactant makers, and construction-chemical formulators. The 2010s and early 2020s saw a series of capacity and integration upgrades, culminating in a facility upgrade whose first full year of operation was 2024 - the event that unlocked the ~85% jump in glycol volumes and the near-fivefold profit surge that year. Management's FY2025 message was that this build-out phase is essentially complete: it explicitly stated it is not embarking on new large-scale expansion and is instead focused on running the existing assets hard.

Geographies and markets. The overwhelming majority of demand is domestic East China, by design - EO's transport hazard means the customer base is local. The company also sells to and is described across filings as serving Mainland China, Japan, Singapore and international buyers for the more transportable products (glycol, PP, by-products), but the merchant-EO and surfactant heart of the business is a regional cluster play, not an export play.

Milestones that changed the business: founding in 2003 to plug the East China EO gap; Hong Kong listing in September 2010 (funding scale-up); build-out of the ~1.6 Mt EO and ~1 Mt EO/EG single-train units into the largest of their kind in China; the facility upgrade whose first full year (2024) reset earnings power; and the FY2025 pivot from build to defend and return cash.

4. Customers

Who buys. Three broad customer types, each with a different logic:

• Polyester and PET producers buy ethylene glycol as a bulk raw material. This is a price-and-availability purchase made by procurement teams; the product is a commodity, switching is easy, and the relationship is about reliable local supply at market price.
• Surfactant, detergent and agrochemical formulators, and PCE water-reducer makers buy merchant EO and surfactant intermediates. These buyers care about consistent quality and dependable local delivery of a hazardous molecule they cannot safely source from far away. The decision sits with technical procurement and R&D, and once a formulator has qualified a supplier's EO grade into its recipe, it is reluctant to re-qualify.
• Plastics converters and fuel blenders buy PP, MTBE and C4/butadiene - again largely price-driven commodity purchases, plus tolling customers who bring their own feedstock.

Why they choose Sanjiang. For the EO/surfactant customers, the reasons are proximity, scale reliability, and safety track record. Because EO cannot be shipped long distances, a Yangtze-Delta formulator's realistic supplier set is short, and a large, established, privately run producer that keeps its train full is a dependable anchor. For the commodity legs (glycol, PP, by-products), the reason is simpler: competitive local pricing.

Switching costs. Highest in the merchant EO and surfactant-intermediate relationships, where qualification testing, formulation lock-in, and the hazard logistics of alternative supply create real stickiness. Lowest in glycol and by-products, which are fungible commodities bought on spot economics. This split is the whole story of the company's margin profile: the sticky, higher-value EO/surfactant book is what management leans on when the commodity legs get commoditised.

Concentration and contract structure. The FY2025 commentary is the key tell here. Management explicitly emphasised "contract-based sales stability" as a pillar of its new defensive strategy - signalling a deliberate shift toward longer-term supply contracts rather than pure spot exposure, to smooth revenue through the cycle. That implies the customer base is diversified across many local buyers (no single dominating name has been flagged as a concentration risk), with a growing share of volume placed under contract to reduce the whiplash of merchant-market pricing. The mix of contract plus spot plus tolling fee income gives the business three different revenue textures layered on one asset.

5. Competitive Landscape

The Chinese EO/EG market is structurally dominated by the state oil majors and increasingly by a wave of new private mega-crackers, with Sanjiang occupying a specific niche: one of the larger privately owned merchant EO and surfactant-intermediate suppliers, anchored in the highest-demand region.

At the top of the industry sit Sinopec and PetroChina and their subsidiaries and joint ventures (Sinopec Zhenhai, Yangzi, Shanghai Petrochemical, Jinling), which historically controlled on the order of two-thirds of Chinese EO capacity. These players make EO and glycol as part of vast integrated refinery-petrochemical complexes. Alongside them, private merchant EO specialists such as Ningbo Heyuan compete directly for the surfactant-and-construction-chemical EO buyer that is Sanjiang's sweet spot. On the bulk glycol and olefin side, Sanjiang is a small player against the new privately owned integrated giants - Satellite Chemical, Hengli Petrochemical, Rongsheng, Wanhua Chemical - whose scale and upstream integration set the commodity price it must accept.

Where Sanjiang wins: in merchant EO and surfactant intermediates in the Yangtze River Delta, where its combination of a very large single EO train, an embedded local customer cluster, safety/permitting track record, and downstream surfactant integration is genuinely hard to replicate. This is a location-and-hazard moat more than a technology moat.

Where Sanjiang loses: in bulk ethylene glycol and olefin by-products, where it is a price-taker against far larger, upstream-integrated producers who buy or make their own ethylene more cheaply. When Chinese glycol and olefin capacity floods the market - as it did into FY2025 - Sanjiang's commodity legs get squeezed and it has no cost advantage to defend them. It also does not own its ethylene, so it is exposed to the ethylene-to-product spread from the wrong side when feedstock is dear and products are cheap.

Barriers to entry are high for merchant EO specifically (hazard logistics, silver-catalyst process know-how, safety permitting, capital, and the need to be physically inside a customer cluster) but low-to-moderate for the commodity glycol/olefin legs, where China has been adding capacity aggressively.

(Market caps are peer-size references only, drawn from mid-2026 data, and move constantly. Approximate figures are marked; Ningbo Heyuan and Befar are unlisted.)

The structural shift underway is Chinese olefin/glycol overcapacity from the new private mega-crackers, which is compressing commodity spreads industry-wide. That is a headwind Sanjiang cannot fix - it can only lean harder into its defensible merchant-EO and surfactant niche and run its assets at high utilisation, which is exactly what the FY2025 strategy pivot describes.

6. Industry

What drives demand. Ethylene oxide sits at the base of three demand pyramids. Historically the largest EO outlet in China was ethylene glycol (once ~68% of EO consumption), which feeds polyester fibre and PET packaging - so a chunk of demand tracks textiles and consumer packaging. The two commodity-EO outlets are nonionic surfactants (~35% of consumption, tied to detergents, textiles, agrochemicals, personal care) and, the fastest-growing leg, polycarboxylate (PCE) superplasticiser polyether monomers used in concrete - which by more recent estimates have grown to command something like 40%+ of EO demand. PCE demand is driven by construction activity and the shift to pumpable, high-slump-retention concrete for high-rise and infrastructure work. So Sanjiang's demand base is a blend of polyester (consumer), detergents (staples), and construction (cyclical infrastructure/property).

Size and structure. China is the world's largest EO/EG market and produces roughly 35% of global ethylene output. The EO segment has historically been a near-oligopoly led by Sinopec and PetroChina (~two-thirds of capacity), with private players like Sanjiang and Ningbo Heyuan taking the merchant-supply balance. Independent market studies (ResearchInChina, Research and Markets) have repeatedly profiled Sanjiang as one of the named major Chinese EO producers.

Supply-chain position. Sanjiang is a midstream converter: it buys ethylene and processes olefin streams, makes EO and derivatives, and sells to downstream formulators and polyester makers. It does not own upstream ethylene, which is both a capital saving and its central vulnerability - the ethylene-to-product spread is set by others.

Regulation. EO's hazard classification means the industry is shaped by safety permitting, environmental controls, and transport restrictions - which raise entry barriers and concentrate merchant supply near demand. Chinese chemical-safety and environmental enforcement has tightened over the past decade, favouring larger, compliant incumbents.

Cyclicality. This is a commodity petrochemical business whose profitability is a spread game: product prices minus ethylene/feedstock cost. Spreads swing hard with the global petrochemical cycle, crude/ethylene prices, and Chinese capacity additions. The recent cycle has been ugly on the commodity end - Chinese olefin and glycol overcapacity plus soft downstream demand drove EO prices to record lows and compressed spreads into FY2025.

Tailwinds: long-run construction-chemical (PCE) demand, detergent/surfactant staples demand, and consolidation favouring safe, compliant incumbents. Headwinds: a wave of new private-cracker glycol/olefin capacity crushing commodity spreads, and the company's lack of upstream ethylene integration.

7. Growth Triggers

Drawn from the six half-yearly results announcements and their management discussion. As noted, no earnings-call transcripts exist for this issuer; these are the forward-looking statements management made in its results filings.

• First full year of the upgraded facility ramping to full utilisation (FY2024 results, ~March 28, 2025). The 2024 upgrade lifted glycol volume ~85% and butadiene volume ~105%; management framed high utilisation of the upgraded asset as the earnings driver going forward. Repeated as the core of the FY2025 strategy.

• Shift toward contract-based sales for revenue stability (FY2025 results, ~March 28, 2026). Management named "contract-based sales stability" as a pillar of the new strategy - i.e. converting more volume from spot to term contracts.

  Management described prioritising "high utilisation of core assets, flexible feedstock and product allocation, contract-based sales stability, and deleveraging via operating cash flow." (FY2025 results announcement)

• Flexible feedstock and product allocation to defend margin through the cycle (FY2025 results, ~March 28, 2026). Explicit intent to swing output between EO, glycol, PP and C4/butadiene toward the widest spread rather than chase volume in any one product.

• Downstream integration and logistics optimisation (FY2025 results, ~March 28, 2026). Management said it aims to strengthen its position by "optimising logistics and downstream integration" - pushing further into higher-value surfactant/PCE derivatives off its own EO rather than selling loose molecules.

• Deleveraging funded by operating cash flow (FY2025 results, ~March 28, 2026). A stated plan to use cash generation to reduce debt and strengthen the balance sheet - a financial trigger for future earnings quality rather than a volume trigger.

• Progressive increase in the dividend payout ratio (FY2025 results, ~March 28, 2026). Management said it "aims to progressively raise its payout ratio," pairing the resumed dividend with an intent to grow it.

  "...aims to progressively raise its payout ratio... seeking to strengthen its financial position without embarking on new large-scale expansion projects." (FY2025 results announcement)

Note what is absent: there is no new-plant commissioning, no new-market entry, and no capacity-expansion trigger. Management has explicitly said it is not launching large new projects. The growth story from here is utilisation, mix, contracts, deleveraging and capital return - an optimisation story, not an expansion story.

8. Key Risks

1. Commodity spread compression (high probability, moderate-to-severe drag). This is the defining risk. The company buys ethylene and sells EO/glycol/olefins; its profit is the spread between them. Chinese overcapacity in glycol and olefins plus soft downstream demand can crush that spread regardless of how well the plant runs. This is not hypothetical - it is exactly what happened in FY2025, when management attributed the profit slide to "margin compression in ethylene oxide and several olefin and aromatics by-product lines and lower ethylene contribution." With no upstream ethylene of its own, Sanjiang has no cost cushion when this recurs.

2. Lack of upstream integration (structural, permanent). Larger rivals (Satellite, Hengli, Sinopec) make or cheaply source their own ethylene. Sanjiang takes feedstock at market. In a dear-feedstock/cheap-product environment it is squeezed from both ends, while integrated peers keep their cracker margin. This caps mid-cycle profitability and makes downcycles sharper.

3. Single-site, single-hazard concentration (low probability, catastrophic). Nearly all production is one complex in Jiaxing handling a highly hazardous, flammable, carcinogenic molecule. A serious process-safety incident, environmental breach, or forced regulatory shutdown would hit essentially all revenue at once. The hazard moat that keeps competitors out is the same hazard that concentrates operational risk.

4. Volume-led, low-margin earnings quality. FY2025 gross margin was reported around 4.9% on a large revenue base. At that thinness, a small move in product or feedstock prices swings profit dramatically (the flip side of the FY2024 fivefold surge). The business is inherently a low-margin, high-throughput commodity converter, and earnings will stay volatile.

5. Cyclical downstream demand. A meaningful share of EO ends up in construction admixtures (PCE). A prolonged Chinese property/infrastructure slowdown would soften one of the company's better demand legs at the same time as commodity oversupply hits the other legs - a correlated downside.

6. Governance/family control. The founding Guan/Han family controls the company through Yihao Development (~45%). Concentrated founder control aligns insiders with the stock (see Section 11) but leaves minority holders dependent on the family's capital-allocation discipline; the dividend and buyback posture is set by them.

9. Walk the Talk

Six periods used: H1 2023 (Sept 2023), FY2023 (March 2024), H1 2024 (Aug 2024), FY2024 (March 2025), H1 2025 (Aug 2025), FY2025 (March 2026). No earnings-call transcripts exist; the assessment is built from the management discussion in each half-yearly results announcement.

The arc across these six filings is that of a management team whose fortunes are driven far more by the petrochemical cycle and a big capex bet coming online than by fine-tuned guidance - and, importantly, one that has not over-promised.

Coming out of H1 2023, the company had swung back to profit after a weak stretch, and the narrative was about the upgraded facility that was being brought fully online. Through FY2023 the story was still transitional - a rebuilding year. The credibility test was FY2024, and here management delivered emphatically: the first full year of the upgraded facility produced exactly the volume unlock they had pointed to, with ethylene glycol volume up ~85% and butadiene up ~105%, and net profit up nearly fivefold. That is a case of a large operational promise (the upgrade would transform throughput) being kept, visibly and measurably.

Guidance implied across H1 2023-FY2023: the upgraded facility would step-change volumes once running at full rate. Outcome (FY2024): glycol volume +~85%, butadiene +~105%, net profit +~482%. Delivered.

The more revealing test is what happened next, because FY2024's blowout was never going to repeat. Into H1 2025 the company actually posted a strong half - net profit up ~96% year-on-year on roughly flat revenue - which suggested the upgraded asset was still earning well. But FY2025 revealed that the second half of 2025 was weak: full-year net profit fell ~23.5% and gross margin thinned to ~4.9% as EO and by-product spreads compressed. Crucially, management did not spin this. It named the cause plainly (margin compression in EO and olefin/aromatic by-products, lower ethylene contribution) and responded with a coherent, conservative strategy shift rather than a promise of a quick rebound: high utilisation, flexible product allocation, contract-based sales, deleveraging, no new big projects, and a resumed-and-rising dividend.

"The company is prioritising a defensive, cash-focused strategy... seeking to strengthen its financial position without embarking on new large-scale expansion projects." (FY2025 results)

That statement matters for credibility because it is the opposite of empire-building. A management team that had just enjoyed a fivefold profit year could easily have announced a big new capacity project into the cycle; instead it chose to defend cash, return capital, and shrink risk. And it backed the words with actions in the same window: it resumed a dividend (HK5 cents final for FY2025), bought back shares (October 2025), and the founders bought stock in the open market (2026). The talk (defend, deleverage, return cash) matches the walk (buyback, dividend, insider buying).

Assessment: This is management that under-promises and lets the cycle and the asset do the talking. It made one big operational commitment (the upgrade would transform volumes) and delivered it. It did not manufacture false optimism when FY2025 turned down - it diagnosed the problem accurately and pivoted to a defensive posture that it has, so far, backed with real capital-allocation moves. The main caveat is that so much of the outcome is cycle-driven and outside management's control, so "walking the talk" here is less about hitting precise guidance numbers (they don't give many) and more about honest disclosure and disciplined capital allocation - on which the record is good.

10. Shareholder Friendliness Index

Dividends. The signal event is FY2025: the company proposed a final dividend of HK5 cents per share and explicitly stated it "aims to progressively raise its payout ratio." For the prior years, the company paid little to no dividend (aggregator data widely listed it as a non-payer through the FY2022-FY2024 window), consistent with a business that was ploughing cash into its facility upgrade. I could not independently verify a per-share dividend for each of FY2022, FY2023 and FY2024 from primary filings within the search budget, and I will not estimate them; the safe reading, well supported by the FY2025 announcement, is that FY2025's HK5 cents represents an initiation/resumption of a cash return, paired with a stated intent to grow it - a deliberate posture change now that the capex phase is over.

Buybacks and dilution. The company executed open-market share repurchases in the second half of 2025: an October 2025 buyback of 1,000,000 shares for about HK$2.52 million (roughly HK$2.46-2.55 per share), with the shares slated for cancellation (share-count reducing, the shareholder-friendly form). This falls inside the recent window; older programmes were not separately identified in primary filings within the budget, so I am not asserting a three-year buyback history beyond this. Net of buybacks and any option activity, the share count appears flat-to-slightly-shrinking rather than diluting - there is no evidence of ongoing equity issuance eroding minority holders. (Buyback figures here combine a web search of exchange announcements and financial news; no MoatMap database block was provided for this issuer.)

Verdict: Returns Capital (newly, and modestly) - after years of retaining cash for the plant upgrade, FY2025 marks a genuine pivot to shareholder returns, evidenced by a resumed-and-rising dividend, a share buyback for cancellation, and founder open-market buying, all in the same window.

11. Insider Activities

Venue: Hong Kong (HKEX). No MoatMap insider/buyback block was provided for this issuer, so the data below is assembled from HKEX-adjacent disclosures and financial-data aggregators reporting the exchange's Disclosure of Interests filings. Where I could not confirm an exact filing reference, I say so.

Over the last ~12 months the picture is unambiguous: insiders and the company itself have been net buyers of the stock, at prices well below the October 2025 buyback level, during a period when the share price had fallen alongside the FY2025 profit dip.

Buys - reading the signal. The standout is the founder and controlling shareholder, Guan Jianzhong, buying ~2 million shares on the open market at ~HK$1.93 in April 2026 - the single largest insider purchase in the recent window, adding meaningfully (~8.7%) to his direct stake, and coming after the FY2025 profit decline had knocked the price down. This is a very bullish signal: a founder who already controls the company through Yihao Development (~45%) choosing to buy more personal stock in the open market at a depressed price is the strongest form of conviction, because he has the most inside knowledge of the plant, the order book, and the cycle. It is reinforced by an executive director (Chen Xian) also buying in June 2026 - a second, independent insider putting personal money in within roughly the same window, which qualifies as cluster buying and strengthens the read. Aggregator data corroborates that insiders were net buyers by roughly HK$3.4 million over the trailing 12 months.

Sells. No material insider selling was identified in the trailing 12 months. There is no disclosed pattern of directors or the controlling family reducing stakes.

Net assessment. Insiders are clearly net buyers, the activity is led by the founder/controlling shareholder and joined by an executive director (concentrated at the top but with a corroborating second name), and it is occurring at prices below the company's own October 2025 buyback level, i.e. into weakness. Combined with the company's own buyback-for-cancellation and the resumed dividend, this is a coherent, aligned pattern. Plain-language read: bullish insider signal - the people who know the business best were buying it after the market marked it down.

12. Scenarios

Bull case. The petrochemical cycle turns. Chinese olefin and glycol overcapacity gets absorbed as weaker, older units are shut and downstream demand recovers, and EO/by-product spreads widen back out. Sanjiang, running its upgraded single-train complex at high utilisation, captures the recovery with operating leverage - just as FY2024 showed it can, when the same asset base produced a near-fivefold profit jump on a mix and volume swing. Meanwhile the deliberate tilt toward higher-value surfactant and PCE water-reducer derivatives, plus more term contracts, smooths the ride and lifts blended margin above the thin commodity floor. Construction-admixture demand for PCE keeps growing structurally. The balance sheet delevers on operating cash flow, and the newly resumed dividend ratchets up year after year as promised. Insiders who bought at ~HK$1.60-1.93 look prescient. The story becomes a disciplined, cash-generative niche EO champion that returns capital instead of chasing capacity.

Base case. The commodity cycle stays soft-to-mixed for a while. Bulk glycol and olefin by-product spreads remain under pressure from Chinese oversupply, so headline profitability stays thin and volatile, but the plant runs full, the surfactant and processing legs stay resilient, and product-swing flexibility keeps the site from posting losses. Management does exactly what it said in FY2025: no big new projects, run the assets hard, put more volume under contract, pay down debt, and keep a modest, gradually rising dividend plus opportunistic buybacks. Earnings bounce around with the ethylene-to-product spread but the business is stable, self-funding, and shrinking its share count at the margin. Nothing dramatic breaks and nothing dramatically re-rates; it is a well-run, cyclical, low-margin converter that returns cash.

Bear case. Chinese olefin and glycol overcapacity gets worse as the new private mega-crackers keep ramping, and spreads stay compressed for years. Because Sanjiang owns no upstream ethylene, it is squeezed from both ends and its ~5% gross margin gets thinner still, tipping the commodity legs into losses that the surfactant book cannot fully offset. A prolonged Chinese property and infrastructure downturn simultaneously softens PCE water-reducer demand, hitting one of the better legs. The single Jiaxing site's concentration turns from moat to liability if a process-safety or environmental incident forces a shutdown of a hazardous EO unit, taking most of revenue offline at once. In that world the resumed dividend gets frozen or cut to protect the balance sheet, the buyback stops, and the founder's open-market buying looks early rather than smart. The business survives - it is asset-backed and family-controlled - but it becomes a value trap: a thin-margin commodity converter with no cost advantage in an oversupplied market.